• Rising prevalence in EU5 markets of neuropathic pain (NP) associated with multiple conditions represents commercial opportunities for drug manufacturers. However, growing generic presence among currently available drug classes will result in increasing market access challenges for branded therapies.
• Late-phase emerging agents will struggle to clinically differentiate themselves from current therapies, particularly to market access authorities, but the potential patient share could be considerable for new analgesics that convincingly demonstrate efficacy and/or tolerability benefits over existing therapies and secure favourable reimbursement terms.
• This research examines access and reimbursement challenges for emerging NP agents in the EU5.

Authors: Spadafora J, A.L.M., Kiernan B, Ph.D., Cox J, Ph.D.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now